KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBITDA Margin (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBITDA Margin for 13 consecutive years, with 1.02% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 8035.0% year-over-year to 1.02%, compared with a TTM value of 5.43% through Dec 2025, up 13188.0%, and an annual FY2025 reading of 5.43%, up 13188.0% over the prior year.
  • EBITDA Margin was 1.02% for Q4 2025 at Travere Therapeutics, down from 63.66% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 406.89% in Q3 2023 and bottomed at 329.91% in Q1 2024.
  • Average EBITDA Margin over 5 years is 110.78%, with a median of 99.22% recorded in 2021.
  • The sharpest move saw EBITDA Margin skyrocketed 65007bps in 2023, then plummeted -49305bps in 2024.
  • Year by year, EBITDA Margin stood at 32.61% in 2021, then plummeted by -821bps to 235.29% in 2022, then increased by 17bps to 195.25% in 2023, then soared by 59bps to 79.33% in 2024, then surged by 101bps to 1.02% in 2025.
  • Business Quant data shows EBITDA Margin for TVTX at 1.02% in Q4 2025, 63.66% in Q3 2025, and 11.12% in Q2 2025.